Bedel Financial Consulting’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-10
Closed -$1K 953
2020
Q4
$1K Sell
10
-3
-23% -$304 ﹤0.01% 803
2020
Q3
$1K Hold
13
﹤0.01% 780
2020
Q2
$1K Buy
13
+3
+30% +$164 ﹤0.01% 745
2020
Q1
$0 Buy
+10
New +$230 ﹤0.01% 878

Other funds holding MRNA

Bedel Financial Consulting's MRNA Position: Q1 2021 in Review

Bedel Financial Consulting sold out of Moderna (MRNA) in Q1 2021, closing a stake of 10 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in MRNA in Q1 2020 and held it in 4 quarters. The position peaked at $1K in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • Bedel Financial Consulting reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
  • Bedel Financial Consulting sold 10 Moderna shares in Q1 2021, an estimated $1K.
  • Bedel Financial Consulting first reported a position in Moderna in Q1 2020 and held it in 4 quarters.
  • Bedel Financial Consulting's Moderna position peaked at $1K in Q4 2020.
  • 776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Bedel Financial Consulting's 13F filing for Q1 2021, filed 26 Apr 2021.